Washington, DC—A cross-border team of Dentons Health Care lawyers represented the Ronald Reagan UCLA Medical Center in its agreement with Chinese firm Centre Testing International Corp. (CTI) to jointly develop a state-of-the-art genetic and molecular clinical pathology laboratory in Shanghai. This partnership marks the first between a Chinese company and US medical center to create a specialized diagnostics laboratory in China, where it will also be the first of its kind. The lab is expected to open in September of this year.
 
The Dentons team advised UCLA Medical Center in both the US and China throughout the course of the agreement. Washington, DC Health Care partner Gadi Weinreich provided counsel in the US.
 
The agreement pledges both entities to the creation of a jointly-owned company, CTI-Pathology/UCLA Health, which will run the lab to support clinical trials and enhance medical care for Chinese patients with cancer and other diseases. With the capability to run sophisticated genetic and molecular diagnostics tests, the new medical facility aims to exceed the scope of the average lab in China.
 
"This joint venture is founded on UCLA's desire to build strong global relationships that, through education, research and service, improve the health of people and communities throughout the world," said Dr. Tom Rosenthal, chief medical officer for UCLA Health System and co-director of UCLA's Center for World Health.
 
According to the terms of the agreement, UCLA will oversee management and control for quality, while CTI will provide funding and marketing. UCLA pathologists will also train specialists in China to accurately interpret tests in the new facility.

About Dentons

Redefining possibilities. Together, everywhere. For more information visit dentons.com